Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
04 2019
Historique:
received: 05 06 2018
revised: 18 09 2018
accepted: 22 09 2018
pubmed: 28 10 2018
medline: 16 5 2019
entrez: 28 10 2018
Statut: ppublish

Résumé

In 2014, the European Society of Cardiology (ESC) recommended the use of a novel risk prediction model (HCM Risk-SCD) to guide use of implantable cardioverter defibrillators (ICD) for the primary prevention of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). We sought to determine the performance of HCM Risk-SCD by conducting a systematic review and meta-analysis of articles reporting on the prevalence of SCD within 5 years of evaluation in low, intermediate and high-risk patients as defined by the 2014 guidelines (predicted risk <4%, 4%-<6% and ≥6%, respectively). The protocol was registered with PROSPERO (registration number: CRD42017064203). MEDLINE and manual searches for papers published from October 2014 to December 2017 were performed. Longitudinal, observational cohorts of unselected adult patients, without history of cardiac arrest were considered. The original HCM Risk-SCD development study was included a priori. Data were pooled using a random effects model. Six (0.9%) out of 653 independent publications identified by the initial search were included. The calculated 5-year risk of SCD was reported in 7291 individuals (70% low, 15% intermediate; 15% high risk) with 184 (2.5%) SCD endpoints within 5 years of baseline evaluation. Most SCD endpoints (68%) occurred in patients with an estimated 5-year risk of ≥4% who formed 30% of the total study cohort. Using the random effects method, the pooled prevalence of SCD endpoints was 1.01% (95% CI 0.52 to 1.61) in low-risk patients, 2.43% (95% CI 1.23 to 3.92) in intermediate and 8.4% (95% CI 6.68 to 10.25) in high-risk patients. This meta-analysis demonstrates that HCM Risk-SCD provides accurate risk estimations that can be used to guide ICD therapy in accordance with the 2014 ESC guidelines. PROSPERO CRD42017064203;Pre-results.

Identifiants

pubmed: 30366935
pii: heartjnl-2018-313700
doi: 10.1136/heartjnl-2018-313700
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

623-631

Subventions

Organisme : Department of Health
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/12/86/29841
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/15/20/31339
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: MMA reports being supported by an unrestricted educational grant from Sanofi Genzyme, outside the submitted work. LM is an employee and a stakeholder of Health in Code SL. All other authors have nothing to disclose.

Auteurs

Constantinos O'Mahony (C)

The Inherited Cardiac Diseases Unit, Barts Heart Centre, St Bartholomew's Hospital, London, UK.
UCL Centre for Heart Muscle Disease, Institute of Cardiovascular Science, University College London, London, UK.
European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-HEART).

Mohammed Majid Akhtar (MM)

The Inherited Cardiac Diseases Unit, Barts Heart Centre, St Bartholomew's Hospital, London, UK.
European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-HEART).
UCL Centre for Heart Muscle Disease, Institute of Cardiovascular Science, University College London, London, UK.

Zacharias Anastasiou (Z)

Department of Statistical Science, University College London, London, UK.

Oliver P Guttmann (OP)

The Inherited Cardiac Diseases Unit, Barts Heart Centre, St Bartholomew's Hospital, London, UK.
European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-HEART).
UCL Centre for Heart Muscle Disease, Institute of Cardiovascular Science, University College London, London, UK.

Pieter A Vriesendorp (PA)

Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.

Michelle Michels (M)

Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands.

Damiano Magrì (D)

Clinical and Molecular Medicine, University 'La Sapienza', Rome, Italy.

Camillo Autore (C)

Clinical and Molecular Medicine, University 'La Sapienza', Rome, Italy.

Adrián Fernández (A)

Department of Cardiology, Favaloro Foundation University Hospital, Institute of Cardiology and Cardiovascular Surgery, Buenos Aires, Argentina.

Juan Pablo Ochoa (JP)

Department of Cardiology, Favaloro Foundation University Hospital, Institute of Cardiology and Cardiovascular Surgery, Buenos Aires, Argentina.
GRINCAR (Cardiovascular Research Group), University of A Coruña, A Coruña, Spain.
Scientific Department, Health In Code, A Coruña, Spain.

Kevin M W Leong (KMW)

Imperial College Healthcare NHS Trust, London, UK.

Amanda M Varnava (AM)

Imperial College Healthcare NHS Trust, London, UK.

Lorenzo Monserrat (L)

Scientific Department, Health In Code, A Coruña, Spain.
Cardiology Department and Research Unit, A Coruña University Hospital, Galician Health Service, A Coruña, Spain.

Aristides Anastasakis (A)

Unit of Inherited Cardiovascular Diseases, First Department of Cardiology, University of Athens, Athens, Greece.

Pablo Garcia-Pavia (P)

European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-HEART).
Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
University Francisco de Vitoria (UFV), Madrid, Spain.
Centro de Investigacion Biomedica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Claudio Rapezzi (C)

Department of Specialised, Experimental and Diagnostic Medicine, Institute of Cardiology, University of Bologna, Bologna, Italy.

Elena Biagini (E)

Department of Specialised, Experimental and Diagnostic Medicine, Institute of Cardiology, University of Bologna, Bologna, Italy.

Juan Ramon Gimeno (JR)

European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-HEART).
Cardiac Department, University Hospital Virgen Arrixaca, La Alberca (Murcia), Spain.

Giuseppe Limongelli (G)

European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-HEART).
Monaldi Hospital, Second University of Naples, Naples, Italy.

Rumana Z Omar (RZ)

Department of Statistical Science, University College London, London, UK.

Perry M Elliott (PM)

The Inherited Cardiac Diseases Unit, Barts Heart Centre, St Bartholomew's Hospital, London, UK.
European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-HEART).
UCL Centre for Heart Muscle Disease, Institute of Cardiovascular Science, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH